Abstract
This study was contributed to assess clinical outcomes related to the role of biologic therapies, targeted therapies, regenerative medicine, and novel drug development in the treatment of rheumatology patients. Patients and methods: A cross-sectional study of 80 rheumatology different hospitals in Iraq analyzed demographic and clinical data from February 2022 to September 2023. The study included 80 cases who underwent modern treatments and methods within the disease management program. The patients were categorized into remission, low, moderate, and high disease severity. Common symptoms included joint pain, swelling, decreased range of motion, fatigue, muscle weakness, fever, numbness, skin rash, weight loss, and difficulty with daily activities. Treatment data included corticoids, cDMARD, bDMARD, and cDMARD combined bDMARD. The study also assessed patients' quality of life, ranging from 0 to 100, based on physical function, psychological function, emotional and social aspects, and daily activity. A multivariate analysis of risk factors affecting patients with rheumatic diseases was performed. Results: Our results shown that males were 16 cases and females were 64 cases, the smoking rate were 30%, obesity was 50%, hypertension was 80%, diabetes was 55%, and cerebrovascular disease was 30%, and the most common symptoms of rheumatic disease which distribute into patients swelling and tenderness in the joints was 80%, joint pain, and stiffness was 85%, and fatigue was 60%, types of treatments used in patients with rheumatology which contain corticoids included 8 cases, cDMARD included 56 cases, bDMARD included 4 cases, and cDMARD combined bDMARD included 12 cases, and we identify activity rheumatic disease which classified into remission got 36 cases, low got 20 cases, moderate got 16 cases, and high got 8 cases. Conclusion: Patients with rheumatic diseases have benefited from biological therapies, targeted therapies, regenerative medicine, and novel drug development.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
